文献速递间质性肺疾病

KIF15罕见与常见变异增加特发性肺纤维化遗传风险

Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

该研究通过全外显子组基因负荷分析、单变异关联检验、KIF15功能实验及人肺单细胞RNA测序,在1,725例病例和23,509例对照中发现KIF15罕见有害变异与IPF关联,并在2,966例病例和29,817例对照的荟萃分析中确认KIF15及三个端粒相关基因的作用;常见变异rs74341405亦与IPF风险相关。

要点

  • KIF15罕见有害变异与IPF风险相关(OR 4.9,95%CI 2.7-8.8)。
  • KIF15常见变异rs74341405与IPF风险相关(OR 1.6,95%CI 1.4-1.9)。
  • KIF15代表非端粒酶细胞增殖通路参与IPF易感性。

核心结论

  • KIF15的罕见有害变异和常见变异均与IPF易感性相关,揭示了一条非端粒酶的细胞增殖通路。

研究设计与样本

  • 全外显子组基因负荷分析纳入1,725例病例和23,509例对照。
  • 发现与复制队列荟萃分析纳入2,966例病例和29,817例对照。
  • 研究还进行了单变异关联检验、KIF15功能实验和人肺单细胞RNA测序。

主要发现

  • 基因负荷分析鉴定出KIF15及三个端粒相关基因(TERT、RTEL1、PARN)的罕见有害变异与IPF相关。
  • KIF15罕见有害变异在常染色体显性模型下OR为4.9(95%CI 2.7-8.8,P=2.55×10^-7)。
  • KIF15罕见蛋白截短变异OR为7.6(95%CI 3.3-17.1,P=8.12×10^-7)。
  • KIF15内含子常见变异rs74341405与IPF风险相关(OR 1.6,95%CI 1.4-1.9,P=5.63×10^-10)。
  • 杂合携带常见变异的淋巴细胞样细胞KIF15表达降低且细胞生长速率下降;IPF患者复制性上皮细胞中KIF15表达减少。

临床怎么用

  • KIF15变异可作为IPF遗传风险评估的候选标志物,尤其关注罕见有害变异和rs74341405。
  • KIF15通路提示非端粒酶依赖的细胞增殖机制可能成为IPF潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Genetic studies of idiopathic pulmonary fibrosis (IPF) have improved our understanding of this disease, but not all causal loci have been identified. Objectives: To identify genes enriched with rare deleterious variants in IPF and familial pulmonary fibrosis. Methods: We performed gene burden analysis of whole-exome data, tested single variants for disease association, conducted KIF15 (kinesin family member 15) functional studies, and examined human lung single-cell RNA sequencing data. Measurements and Main Results: Gene burden analysis of 1,725 cases and 23,509 control subjects identified heterozygous rare deleterious variants in KIF15, a kinesin involved in spindle separation during mitosis, and three telomere-related genes (TERT [telomerase reverse transcriptase], RTEL1 [regulator of telomere elongation helicase 1], and PARN [poly(A)-specific ribonuclease]). KIF15 was implicated in autosomal-dominant models of rare deleterious variants (odds ratio [OR], 4.9; 95% confidence interval [CI], 2.7-8.8; P = 2.55 × 10-7) and rare protein-truncating variants (OR, 7.6; 95% CI, 3.3-17.1; P = 8.12 × 10-7). Meta-analyses of the discovery and replication cohorts, including 2,966 cases and 29,817 control subjects, confirm the involvement of KIF15 plus the three telomere-related genes. A common variant within a KIF15 intron (rs74341405; OR, 1.6; 95% CI, 1.4-1.9; P = 5.63 × 10-10) is associated with IPF risk, confirming a prior report. Lymphoblastoid cells from individuals heterozygous for the common variant have decreased KIF15 and reduced rates of cell growth. Cell proliferation is dependent on KIF15 in the presence of an inhibitor of Eg5/KIF11, which has partially redundant function. KIF15 is expressed specifically in replicating human lung cells and shows diminished expression in replicating epithelial cells of patients with IPF. Conclusions: Both rare deleterious variants and common variants in KIF15 link a nontelomerase pathway of cell proliferation with IPF susceptibility.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Zhang D, Povysil G, Kobeissy PH, et al. Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022. PMID: 35417304. doi:10.1164/rccm.202110-2439OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。